Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418949 · ClinicalTrials.gov registry record · NA
Altering Activation Patterns Post-stroke
A NA study, sponsored by Shirley Ryan AbilityLab.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
NCT02418949: Completed NA study, sponsored by Shirley Ryan AbilityLab.
NCT02418949 is a NA study that has completed, run by Shirley Ryan AbilityLab. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02418949, a NA study, has completed, sponsored by Shirley Ryan AbilityLab.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (AMP) is used to encourage increased voluntary muscle control and strength.
Primary Outcome
GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds.
Interventions
- DRUG Cyproheptadine
- DRUG Placebo for Cyproheptadine
- OTHER Active Movement Practice (AMP)
- OTHER Passive Cyclical Stretching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-03-23 |
| Phase | NA |
What the finished NCT02418949 record still lists
NCT02418949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyproheptadine is the first listed.
NCT02418949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02418949 about?
NCT02418949 is a clinical study titled "Altering Activation Patterns Post-stroke". This study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (AMP) is used to encourage increased voluntary muscle control and strength.
What is the current status of trial NCT02418949?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2015-11. Estimated completion is 2022-03-23.
What interventions are being tested in trial NCT02418949?
The interventions under investigation include: Cyproheptadine (DRUG), Placebo for Cyproheptadine (DRUG), Active Movement Practice (AMP) (OTHER), Passive Cyclical Stretching (OTHER).
Who is sponsoring clinical trial NCT02418949?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02418949's enrollment target sits among peer trials
96 925th of 2000 higher than 1,070 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia